Abstract:Uncontrolled neuroinflammation mediates traumatic brain injury (TBI) pathology and impairs recovery. Interleukin-6 (IL-6), a pleiotropic inflammatory regulator, is associated with poor clinical TBI outcomes. IL-6 operates via classical-signaling through membrane-bound IL-6 receptor (IL-6R) and trans-signaling through soluble IL-6 receptor (s)IL-6R. IL-6 trans-signaling specifically contributes to neuropathology, making it a potential precision therapeutic TBI target. Soluble glycoprotein 130 (sgp130) prevents IL-6 trans-signaling, sparing classical signaling, thus is a possible treatment. Mice received either controlled cortical impact (CCI) (6.0 ± 0.2 m/s; 2 mm; 50-60ms) or sham procedures. Vehicle (VEH) or sgp130-Fc was subcutaneously administered to sham (VEH or 1 μg) and CCI (VEH, 0.25 μg or 1 μg) mice on days 1, 4, 7, 10 and 13 post-surgery to assess effects on cognition [Morris Water Maze (MWM)] and ipsilateral hemisphere IL-6 related biomarkers (day 21 post-surgery). CCI + sgp130-Fc groups (0.25 μg and 1 μg) were combined for analysis given similar behavior/biomarker outcomes. CCI + VEH mice had longer latencies and path lengths to the platform and increased peripheral zone time versus Sham + VEH and Sham + sgp130-Fc mice, suggesting injury-induced impairments in learning and anxiety. CCI + sgp130-Fc mice had shorter platform latencies and path lengths and had decreased peripheral zone time, indicating a therapeutic benefit of sgp130-Fc after injury on learning and anxiety. Interestingly, Sham + sgp130-Fc mice had shorter platform latencies, path lengths and peripheral zone times than Sham + VEH mice, suggesting a beneficial effect of sgp130-Fc, independent of injury. CCI + VEH mice had increased brain IL-6 and decreased sgp130 levels versus Sham + VEH and Sham + sgp130-Fc mice. There was no treatment effect on IL-6, sIL6-R or sgp130 in Sham + VEH versus Sham + sgp130-Fc mice. There was also no treatment effect on IL-6 in CCI + VEH versus CCI + sgp130-Fc mice. However, CCI + sgp130-Fc mice had increased sIL-6R and sgp130 versus CCI + VEH mice, demonstrating sgp130-Fc treatment effects on brain biomarkers. Inflammatory chemokines (MIP-1β, IP-10, MIG) were increased in CCI + VEH mice versus Sham + VEH and Sham + sgp130-Fc mice. However, CCI + sgp130-Fc mice had decreased chemokine levels versus CCI + VEH mice. IL-6 positively correlated, while sgp130 negatively correlated, with chemokine levels. Overall, we found that systemic sgp130-Fc treatment after CCI improved learning, decreased anxiety and reduced CCI-induced brain chemokines. Future studies will explore sex-specific dosing and treatment mechanisms for sgp130-Fc therapy.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore whether selectively inhibiting the trans - signaling of interleukin - 6 (IL - 6) by systematically administering soluble glycoprotein 130 (sgp130 - Fc) can promote behavioral and neuroinflammatory benefits in a mouse model of severe traumatic brain injury (TBI). Specifically, the study aims to evaluate whether sgp130 - Fc treatment can improve cognitive function after TBI, reduce anxiety - like behavior, and decrease the levels of brain - inflammatory cytokines associated with TBI. ### Main research questions: 1. **Improvement of cognitive function**: Evaluate whether sgp130 - Fc treatment can improve the learning and memory abilities of mice after TBI through the Morris water maze test. 2. **Reduction of anxiety - like behavior**: Evaluate whether sgp130 - Fc treatment can reduce anxiety - like behavior after TBI by reducing the time in the peripheral area in the Morris water maze test. 3. **Reduction of inflammatory markers**: Evaluate whether sgp130 - Fc treatment can reduce the inflammatory response caused by TBI by measuring the levels of IL - 6 - related biomarkers and inflammatory chemokines in the brain. ### Research background: - **Role of IL - 6**: IL - 6 is acutely and chronically up - regulated after TBI and is associated with poor clinical outcomes. IL - 6 functions through classical signaling and trans - signaling pathways, and the trans - signaling is considered to play a major role in neuropathology. - **Mechanism of action of sgp130 - Fc**: sgp130 - Fc is a fusion protein that can selectively target sIL - 6R, thereby preventing trans - signaling while retaining the beneficial functions of classical signaling. ### Research methods: - **Animal model**: Adult male C57BL/6J mice were used and divided into five groups: Sham + vehicle (Sham + VEH), Sham + 1 µg sgp130 - Fc (Sham + 1 µg), controlled cortical impact + vehicle (CCI + VEH), CCI + 0.25 µg sgp130 - Fc (CCI + 0.25 µg), CCI + 1 µg sgp130 - Fc (CCI + 1 µg). - **Treatment protocol**: sgp130 - Fc or vehicle was subcutaneously injected once every 3 days starting from the first day after surgery, for a total of 5 times. - **Behavioral test**: Learning and memory abilities as well as anxiety - like behavior were evaluated through the Morris water maze test. - **Biomarker detection**: Brain tissues were collected on the 21st day after surgery to detect the levels of IL - 6, sIL - 6R, sgp130, and the inflammatory chemokines MIG, IP - 10, and MIP - 1β. ### Research results: - **Cognitive function**: Mice in the CCI + VEH group showed longer latency and path length in the Morris water maze test, while mice in the CCI + sgp130 - Fc group had shorter latency and path length, indicating that sgp130 - Fc treatment improved learning and memory abilities. - **Anxiety - like behavior**: Mice in the CCI + VEH group spent a longer time in the peripheral area, while mice in the CCI + sgp130 - Fc group spent a shorter time, indicating that sgp130 - Fc treatment reduced anxiety - like behavior. - **Inflammatory markers**: The level of IL - 6 in the brain of mice in the CCI + VEH group was increased, while the level of sgp130 was decreased. The levels of sIL - 6R and sgp130 in the CCI + sgp130 - Fc group were increased, and the levels of MIG, IP - 10, and MIP - 1β were decreased, indicating that sgp130 - Fc treatment reduced the inflammatory response. ### Conclusion: This study shows that systematic administration of sgp130 - Fc can improve cognitive function after TBI, reduce anxiety - like behavior, and decrease the levels of inflammatory markers in the brain by selectively inhibiting the trans - signaling of IL - 6. These findings provide important experimental evidence for the development of new treatment methods for TBI.

Exploratory assessment of the effect of systemic administration of soluble glycoprotein 130 on cognitive performance and chemokine levels in a mouse model of experimental traumatic brain injury

Peripheral Inflammatory Markers in Patients with Prolonged Disorder of Consciousness after Severe Traumatic Brain Injury.

Inhibition of Cathepsin S Produces Neuroprotective Effects after Traumatic Brain Injury in Mice

Granulocyte- Macrophage Colony-Stimulating Factor Reverses Immunosuppression Acutely Following a Traumatic Brain Injury and Hemorrhage Polytrauma in a Juvenile Male Rat Model

CSF1R blockade slows progression of cerebral hemorrhage by reducing microglial proliferation and increasing infiltration of CD8 + CD122+ T cells into the brain

Abstract WMP76: Long-Term Effects of Intracerebral Hemorrhage on Behavior and Inflammation

Effects of Induced Neural Stem Cells on Complement Activation Following Traumatic Brain Injury

Systemic inflammation exacerbates behavioral and histopathological consequences of isolated traumatic brain injury in rats

Administration of monoclonal antibodies neutralizing the inflammatory mediators tumor necrosis factor alpha and interleukin -6 does not attenuate acute behavioral deficits following experimental traumatic brain injury in the rat

TT-301 Inhibits Microglial Activation and Improves Outcome after Central Nervous System Injury in Adult Mice

Transplantation of mesenchymal stem cells genetically engineered to overexpress interleukin-10 promotes alternative inflammatory response in rat model of traumatic brain injury

Elevated Serum Levels of Inflammation-Related Cytokines in Mild Traumatic Brain Injury Are Associated with Cognitive Performance

Sphingolipid changes in mouse brain and plasma after mild traumatic brain injury at the acute phases

Dynamic Changes and Effects of H2S, IGF-1, and GH in the Traumatic Brain Injury

Effects of Stereotaxic Transplantation of Induced Neural Stem Cells Receiving Traumatic Brain Injury Mouse Serum Pre-Treatment on Complement Activation

Abstract WMP74: Inhibition of T Cell Receptor Activation Improves Neurological Outcomes After Intracerebral Hemorrhage

The contribution of stem cell factor and granulocyte colony-stimulating factor in reducing neurodegeneration and promoting neurostructure network reorganization after traumatic brain injury

MULTIMODAL TREATMENT APPROACHES TO COMBINED TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK ALTER POSTINJURY INFLAMMATORY RESPONSE

Microglial Depletion with CSF1R Inhibitor During Chronic Phase of Experimental Traumatic Brain Injury Reduces Neurodegeneration and Neurological Deficits

Integrated Multiomics Analysis Identifies a Novel Biomarker Associated with Prognosis in Intracerebral Hemorrhage

Anti-inflammatory interleukin 1 receptor antagonist concentration in plasma correlates with blood-brain barrier integrity in the primary lesion area in traumatic brain injury patients